Open AccessAtypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition
Author(s) -
Lisa Zimmer,
Uwe Hillen,
Elisabeth Livingstone,
Mario E. Lacouture,
Klaus J. Busam,
Richard D. Carvajal,
Friederike Egberts,
Axel Hauschild,
Mohammed KashaniSabet,
Simone M. Goldinger,
Reinhard Dummer,
Georgina V. Long,
Grant A. McArthur,
André Scherag,
Antje Sucker,
Dirk Schadendorf
Publication year - 2012
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2011.41.1660
Subject(s) - neuroblastoma ras viral oncogene homolog , melanoma , medicine , cancer research , gnaq , vemurafenib , carcinogenesis , targeted therapy , melanocytic nevus , v600e , nevus , cancer , mutation , pathology , metastatic melanoma , gene , biology , biochemistry , colorectal cancer , kras
Selective inhibition of mutant BRAF by using class I RAF inhibitors in patients with metastatic melanoma has resulted in impressive clinical activity. However, there is also evidence that RAF inhibitors might induce carcinogenesis or promote tumor progression via stimulation of MAPK signaling in RAF wild-type cells. We analyzed melanocytic lesions arising under class I RAF inhibitor treatment for dignity, specific genetic mutations, or expression of signal transduction molecules.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom